The tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic with a clinically acceptable safety profile in subjects previously vaccinated with a tetravalent polysaccharide vaccine

International Journal of Infectious Diseases

Volumn 16, Issue 8, 2012, Pages

  Dbaibo, Ghassan ^a   Van der Wielen, Marie ^b   Reda, Mariam ^a   Medlej, Fouad ^a   Tabet, Carelle ^a   Boutriau, Dominique ^b   Sumbul, Anne ^b   Anis, Sameh ^c   Miller, Jacqueline M ^d  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^b GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^c GLAXOSMITHKLINE   (United Kingdom)

^d GLAXOSMITHKLINE   (United States)

Author keywords

Bactericidal activity; Conjugate vaccine; Hyporesponsiveness; Polysaccharide vaccine; Safety; Tetravalent meningococcal vaccine

Indexed keywords

MENINGOCOCCUS VACCINE; POLYSACCHARIDE VACCINE; TETANUS TOXOID;

ADOLESCENT; ADULT; ANTIBODY TITER; ARTICLE; BACTERIAL STRAIN; CHILD; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; IMMUNOGENICITY; INJECTION SITE COLORATION; INJECTION SITE PAIN; INJECTION SITE SWELLING; MALE; MEDICAL RECORD; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; NORMAL HUMAN; PHASE 2 CLINICAL TRIAL; SEROTYPE; SERUM BACTERICIDAL ACTIVITY; SKIN REDNESS;

ADOLESCENT; ADULT; ANTIBODIES, BACTERIAL; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNIZATION, SECONDARY; IMMUNOTOXINS; MALE; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS; POLYSACCHARIDES, BACTERIAL; TETANUS TOXOID; VACCINES, CONJUGATE; YOUNG ADULT;

EID: 84864383952     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2012.04.006     Document Type: Article

References (39)

1. Pollard A.J. Global epidemiology of meningococcal disease and vaccine efficacy. Pediatr Infect Dis J 2004, 23:S274-S279.
2. Harrison L.H., Trotter C.L., Ramsay M.E. Global epidemiology of meningococcal disease. Vaccine 2009, 27:B51-B63.
3. Thulin Hedberg S., Törös B., Fredlund H., Olcén P., Mölling P. Genetic characterisation of the emerging invasive Neisseria meningitidis serogroup Y in Sweden, 2000 to 2010. Euro Surveill 2011, 16. pii: 19885.
4. Vainio A, Toropainen M, Kuusi M, Virolainen A. Characteristics of invasive meningococcal serogroup Y isolates in Finland, 1995-2010. Abstract P037. 11th Meeting of the European Monitoring Group on Meningococci (EMGM), Ljubljana, Slovenia, May 18-20, 2011.
5. Caugant DA, Løvoll Ø, Blystad H. Meningococcal disease in Norway, 2009-2010: emergence of serogroup Y. Abstract P040. 11th Meeting of the European Monitoring Group on Meningococci (EMGM), Ljubljana, Slovenia, May 18-20, 2011.
6. Bidmos F.A., Neal K.R., Oldfield N.J., Turner D.P., Ala'aldeen D.A., Bayliss C.D. Persistence, replacement, and rapid clonal expansion of meningococcal carriage isolates in a 2008 university student cohort. J Clin Microbiol 2011, 49:506-512.
7. Lingappa J.R., Al Rabeah A.M., Hajjeh R., Mustafa T., Fatani A., Al Bassam T., et al. Serogroup W-135 meningococcal disease during the Hajj, 2000. Emerg Infect Dis 2003, 9:665-671.
8. Traoré Y., Njanpop-Lafourcade B.M., Adjogble K.L., Lourd M., Yaro S., Nacro B., et al. The rise and fall of epidemic Neisseria meningitidis serogroup W135 meningitis in Burkina Faso, 2002-2005. Clin Infect Dis 2006, 43:817-822.
9. Harrison L.H. Prospects for vaccine prevention of meningococcal infection. Clin Microbiol Rev 2006, 19:142-164.
10. Ramsay M.E., Andrews N.J., Trotter C.L., Kaczmarski E.B., Miller E. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ 2003, 326:365-366.
11. Pelton S.I., Gilmet G.P. Expanding prevention of invasive meningococcal disease. Expert Rev Vaccines 2009, 8:717-727.
12. Larrauri A., Cano R., Garcia M., Mateo S. Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain. Vaccine 2005, 23:4097-4100.
13. Sow S.O., Okoko B.J., Diallo A., Viviani S., Borrow R., Carlone G., et al. Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans. N Engl J Med 2011, 364:2293-2304.
14. Keyserling H., Papa T., Koranyi K., Ryall R., Bassily E., Bybel M.J., et al. Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents. Arch Pediatr Adolesc Med 2005, 159:907-913.
15. Jackson L.A., Baxter R., Reisinger K., Karsten A., Shah J., Bedell L., et al. Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents. Clin Infect Dis 2009, 49. e1-10.
16. Østergaard L., Lebacq E., Poolman J., Maechler G., Boutriau D. Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15-25 years. Vaccine 2009, 27:161-168.
17. Knuf M., Kieninger-Baum D., Habermehl P., Muttonen P., Maurer H., Vink P., et al. A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children. Vaccine 2010, 28:744-753.
18. Bermal N., Huang L.M., Dubey A.P., Jain H., Bavedkar A., Lin T.Y., et al. Safety and immunogenicity of a tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine in adolescents and adults. HumVaccin 2011, 7:239-247.
19. Baxter R., Baine Y., Ensor K., Bianco V., Friedland L.R., Miller J.M. Immunogenicity and safety of an investigational quadrivalent meningococcal ACWY tetanus toxoid conjugate vaccine in healthy adolescents and young adults 10-25 years of age. Pediatr Infect Dis J 2011, 30:e41-e48.
20. Memish Z.A., Dbaibo G., Montellano M., Verghese V.P., Jain H., Dubey A.P., et al. Immunogenicity of a single dose of tetravalent meningococcal serogroups A, C, W-135, and Y conjugate vaccine administered to 2- to 10-year-olds is noninferior to a licensed ACWY polysaccharide vaccine with an acceptable safety profile. Pediatr Infect Dis J 2011, 30:e56-e62.
21. Vesikari T., Karvonen A., Bianco V., Van der Wielen M., Miller J. Tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine is well tolerated and immunogenic when co-administered with measles-mumps-rubella-varicella vaccine during the second year of life: an open, randomized controlled trial. Vaccine 2011, 29:4274-4284.
22. Knuf M., Pantazi-Chatzikonstantinou A., Pfletschinger U., Tichmann-Schumann I., Maurer H., Maurer L., et al. An investigational tetravalent meningococcal serogroups A, C, W-135 and Y-tetanus toxoid conjugate vaccine co-administered with Infanrix™ hexa is immunogenic, with an acceptable safety profile in 12-23 month old children. Vaccine 2011, 29:4264-4273.
23. MacDonald N.E., Halperin S.A., Law B.J., Forrest B., Danzig L.E., Granoff D.M. Induction of immunologic memory by conjugated vs plain meningococcal C polysaccharide vaccine in toddlers: a randomized controlled trial. JAMA 1998, 280:1685-1689.
24. Broker M., Veitch K. Quadrivalent meningococcal vaccines: hyporesponsiveness as an important consideration when choosing between the use of conjugate vaccine or polysaccharide vaccine. Travel Med Infect Dis 2010, 8:47-50.
25. Richmond P., Kaczmarski E., Borrow R., Findlow J., Clark S., McCann R., et al. Meningococcal C polysaccharide vaccine induces immunologic hyporesponsiveness in adults that is overcome by meningococcal C conjugate vaccine. J Infect Dis 2000, 181:761-764.
26. Southern J., Deane S., Ashton L., Borrow R., Goldblatt D., Andrews N., et al. Effects of prior polysaccharide vaccination on magnitude, duration, and quality of immune responses to and safety profile of a meningococcal serogroup C tetanus toxoid conjugate vaccination in adults. Clin Diagn Lab Immunol 2004, 11:1100-1104.
27. Maslanka S.E., Gheesling L.L., Libutti D.E., Donaldson K.B., Harakeh H.S., Dykes J.K., et al. Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. Clin Diagn Lab Immunol 1997, 4:156-167.
28. Borrow R., Balmer P., Miller E. Meningococcal surrogates of protection-serum bactericidal antibody activity. Vaccine 2005, 23:2222-2227.
29. Centers for Disease Control Prevention Inadvertent misadministration of meningococcal conjugate vaccine-United States, June-August 2005. Morb Mortal Wkly Rep 2006, 55:1016-1017.
30. Borrow R., Andrews N., Goldblatt D., Miller E. Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection. Infect Immun 2001, 69:1568-1573.
31. Gheesling L.L., Carlone G.M., Pais L.B., Holder P.F., Maslanka S.E., Plikaytis B.D., et al. Multicenter comparison of Neisseria meningitidis serogroup C anti-capsular polysaccharide antibody levels measured by a standardized enzyme-linked immunosorbent assay. J Clin Microbiol 1994, 32:1475-1482.
32. Melville-Smith M.E., Seagroatt V.A., Watkins J.T. A comparison of enzyme-linked immunosorbent assay (ELISA) with the toxin neutralization test in mice as a method for the estimation of tetanus antitoxin in human sera. J Biol Stand 1983, 11:137-144.
33. Borrow R., Joseph H., Andrews N., Acuna M., Longworth E., Martin S., et al. Reduced antibody response to revaccination with meningococcal serogroup A polysaccharide vaccine in adults. Vaccine 2000, 19:1129-1132.
34. Granoff D.M., Pollard A.J. Reconsideration of the use of meningococcal polysaccharide vaccine. Pediatr Infect Dis J 2007, 26:716-722.
35. Englund J.A., Anderson E.L., Reed G.F. The effect of maternal antibody on the serologic response and the incidence of adverse reactions after primary immunization with acellular and whole-cell pertussis vaccines combined with diphtheria and tetanus toxoids. Pediatrics 1995, 96:580-584.
36. Jodar L., Cartwright K., Feavers I.M. Standardisation and validation of serological assays for the evaluation of immune responses to Neisseria meningitidis serogroup A and C vaccines. Biologicals 2000, 28:193-197.
37. World Health Organization Requirements for meningococcal polysaccharide vaccine (requirements for biological substances no. 23). WHO Tech Rep Ser 1976, 594:72-73.
38. Borrow R., Southern J., Andrews N., Peake N., Rahim R., Acuna M., et al. Comparison of antibody kinetics following meningococcal serogroup C conjugate vaccine between healthy adults previously vaccinated with meningococcal A/C polysaccharide vaccine and vaccine-naive controls. Vaccine 2001, 19:3043-3050.
39. Borrow R., Goldblatt D., Andrews N., Richmond P., Southern J., Miller E. Influence of prior meningococcal C polysaccharide vaccination on the response and generation of memory after meningococcal C conjugate vaccination in young children. J Infect Dis 2001, 184:377-380.